[go: up one dir, main page]

CL2019000625A1 - Combinación de agonistas de fxr. - Google Patents

Combinación de agonistas de fxr.

Info

Publication number
CL2019000625A1
CL2019000625A1 CL2019000625A CL2019000625A CL2019000625A1 CL 2019000625 A1 CL2019000625 A1 CL 2019000625A1 CL 2019000625 A CL2019000625 A CL 2019000625A CL 2019000625 A CL2019000625 A CL 2019000625A CL 2019000625 A1 CL2019000625 A1 CL 2019000625A1
Authority
CL
Chile
Prior art keywords
fxr agonist
agonist combination
fxr
combination
farnesoid
Prior art date
Application number
CL2019000625A
Other languages
English (en)
Inventor
Bryan Laffitte
Andreas Bauer
Patrick Mueller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019000625A1 publication Critical patent/CL2019000625A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN AGONISTA DEL RECEPTOR FARNESOIDE X (FXR) Y OTRO AGENTE TERAPÉUTICO, EN PARTICULAR PARA EL TRATAMIENTO O LA PREVENCIÓN DE ENFERMEDADES O TRASTORNOS HEPÁTICOS.
CL2019000625A 2016-09-14 2019-03-12 Combinación de agonistas de fxr. CL2019000625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662394446P 2016-09-14 2016-09-14

Publications (1)

Publication Number Publication Date
CL2019000625A1 true CL2019000625A1 (es) 2019-05-17

Family

ID=60043251

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000625A CL2019000625A1 (es) 2016-09-14 2019-03-12 Combinación de agonistas de fxr.

Country Status (23)

Country Link
US (1) US20210290610A1 (es)
EP (1) EP3512558A1 (es)
JP (1) JP6878596B2 (es)
KR (1) KR102218498B1 (es)
CN (1) CN109689105A (es)
AR (1) AR109652A1 (es)
AU (2) AU2017328999B2 (es)
BR (1) BR112019004684A2 (es)
CA (1) CA3036760A1 (es)
CL (1) CL2019000625A1 (es)
CO (1) CO2019002245A2 (es)
CR (1) CR20190125A (es)
EC (1) ECSP19016844A (es)
IL (1) IL264628A (es)
JO (1) JOP20190040A1 (es)
MX (1) MX2019003021A (es)
PE (1) PE20190972A1 (es)
PH (1) PH12019500326A1 (es)
RU (1) RU2019110780A (es)
SG (1) SG11201900651PA (es)
TW (1) TW201811372A (es)
WO (1) WO2018051230A1 (es)
ZA (1) ZA201900528B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991990A1 (ru) * 2017-02-24 2020-04-07 Женфит Фармацевтические композиции для комбинированной терапии
JP2021525750A (ja) * 2018-05-31 2021-09-27 ノバルティス アーゲー トロピフェクサーとセニクリビロックとを含む組合せ
MX2022000743A (es) * 2019-07-18 2022-02-14 Enyo Pharma Tratamiento mejorado utilizando eyp001.
CA3165000A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
AP3113A (en) * 2008-11-26 2015-01-31 Pfizer 3-Aminocyclopentanecarboxamides as chemokine receptor modulators
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX364834B (es) * 2013-11-05 2019-05-08 Novartis Ag Composiciones y metodos para modular los receptores x farnesoides.
WO2015138986A1 (en) * 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
CN106999593A (zh) * 2014-09-12 2017-08-01 妥必徕疗治公司 用于纤维化治疗的赛尼克韦罗组合疗法
BR112017011972A2 (pt) * 2014-12-18 2017-12-26 Novartis Ag derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
PL3419624T3 (pl) * 2016-02-22 2021-08-02 Novartis Ag Sposoby stosowania agonistów fxr

Also Published As

Publication number Publication date
KR20190044666A (ko) 2019-04-30
CN109689105A (zh) 2019-04-26
JP2019526644A (ja) 2019-09-19
IL264628A (en) 2019-02-28
EP3512558A1 (en) 2019-07-24
ZA201900528B (en) 2021-06-30
US20210290610A1 (en) 2021-09-23
SG11201900651PA (en) 2019-04-29
KR102218498B1 (ko) 2021-02-22
AU2017328999B2 (en) 2019-12-19
JOP20190040A1 (ar) 2019-03-10
CR20190125A (es) 2019-06-04
PE20190972A1 (es) 2019-07-09
AR109652A1 (es) 2019-01-09
RU2019110780A3 (es) 2020-11-30
MX2019003021A (es) 2019-09-26
CO2019002245A2 (es) 2019-05-31
RU2019110780A (ru) 2020-10-15
BR112019004684A2 (pt) 2019-05-28
AU2020201980A1 (en) 2020-04-09
CA3036760A1 (en) 2018-03-22
ECSP19016844A (es) 2019-03-29
AU2017328999A1 (en) 2019-02-21
WO2018051230A1 (en) 2018-03-22
PH12019500326A1 (en) 2019-11-11
TW201811372A (zh) 2018-04-01
JP6878596B2 (ja) 2021-05-26

Similar Documents

Publication Publication Date Title
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
CL2019000914A1 (es) Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
MX2018004019A (es) Formulacion novedosa y metodos de tratamiento.
SV2017005527A (es) Agente terapéutico para disfunción del lóbulo frontal
AR102494A1 (es) Métodos para tratar enfermedades oculares